Senate backs prostate cancer awareness month—a public health win
S.Res. 436 — A resolution expressing support for the designation of September 2025 as "National Prostate Cancer Awareness Month". · Filed by Mike Crapo (R-ID) · 3 cosponsors · Introduced Oct 6, 2025 · Passed chamber
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This is a Senate resolution expressing support for designating September 2025 as 'National Prostate Cancer Awareness Month.' It documents the scale of prostate cancer in the U.S. (3.3 million men living with it, 1 in 8 lifetime diagnosis risk), notes federal research funding ($7.2 billion to the National Cancer Institute, $75 million to the Defense Department's Prostate Cancer Research Program), and calls on Americans, health organizations, and government to raise awareness about screening and treatment.
Why we flagged it
This is a non-binding commemorative resolution that designates a month for public awareness of a significant health condition. It contains no legislative mechanism, appropriations, or regulatory change—only a call for awareness and continued research support.
What the text implies
- Implicit endorsement of prostate cancer screening may influence clinical practice and patient demand, potentially increasing screening volume and associated healthcare costs (both diagnostic and treatment-related).
- Resolution cites specific federal funding levels ($7.2B to NCI, $75M to DoD program), which may signal congressional intent to maintain or increase these appropriations in future budget cycles.
- Emphasis on 'consultation with a physician regarding benefits and risks of screening' acknowledges ongoing medical debate about PSA screening efficacy and overdiagnosis, but the resolution's overall framing favors awareness and early detection.
Who it affects
Public health awareness campaigns reduce stigma, encourage early detection (which dramatically improves survival rates from 37% to near 100%), and support continued research funding. No direct costs to citizens; the resolution is hortatory and does not impose new taxes or restrictions.
Who stands to gain
- pharmaceutical companies (cancer treatment drugs)
- medical device manufacturers (diagnostic and treatment equipment)
- healthcare providers and hospital systems (screening and treatment services)
- clinical research organizations (funded research contracts)
Named in the bill
National Institutes of Health (NIH), National Cancer Institute (NCI), Department of Defense (DoD), Department of Veterans Affairs (VA), American Cancer Society, Bristol Myers Squibb (BMY), Guardant Health (GH), Pfizer (PFE), DaVita (DVA), Johnson & Johnson (JNJ)
Where it stands
3 cosponsors: 2 Democrats, 1 Republicans.
- Oct 6, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- Oct 6, 2025 — Passed the Senate · Congress.gov: “Passed/agreed to in Senate: Submitted in the Senate, considered, and agreed to without amendment and with a…”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the full bill text on Jul 6, 2026; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“Senate backs prostate cancer awareness month—a public health win” QuorumCivic. https://share.quorumcivic.app/bill/119/sres436 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.